[Federal Register Volume 63, Number 17 (Tuesday, January 27, 1998)]
[Notices]
[Page 3904]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-1942]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 98M-0036]
Xytronyx, Inc.; Premarket Approval of the Periogard Periodontal
Tissue Monitor
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing its
approval of the application by Xytronyx, Inc., San Diego, CA, for
premarket approval, under the Federal Food, Drug, and Cosmetic Act (the
act), of the Periogard Periodontal Tissue Monitor (PTM). After
reviewing the recommendation of the Devices Panel, FDA's Center for
Devices and Radiological Health (CDRH) notified the applicant, by
letter of June 23, 1997, of the approval of the application.
DATES: Petitions for administrative review by February 26, 1998.
ADDRESSES: Written requests for copies of the summary of safety and
effectiveness data and petitions for administrative review to the
Dockets Management Branch (HFA-305), Food and Drug Administration,
12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.
FOR FURTHER INFORMATION CONTACT: Alfred W. Montgomery, Center for
Devices and Radiological Health (HFZ-440), Food and Drug
Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-
1243.
SUPPLEMENTARY INFORMATION: On September 19, 1996, Xytronyx, Inc., San
Diego, CA 92121, submitted to CDRH an application for premarket
approval of the PTM. The device is a visual, periodontal test kit and
is indicated for use as a rapid, chair-side, visual test for the
qualitative determination of aspartate aminotransferase (AST) in
gingival crevicular fluid. The PTM kit detects elevated levels of AST
associated with tissue necrosis. It is intended to be used as an
objective, biochemical adjunct to traditional methods of monitoring
patients to assist in the decision to apply treatment and in the
evaluation of treatment effectiveness.
In accordance with the provisions of section 515(c)(2) of the act
(21 U.S.C. 360e(c)(2)) as amended by the Safe Medical Devices Act of
1990, this premarket approval application (PMA) was not referred to the
Dental Products Panel and/or the Clinical Chemistry and Toxicology
Devices Panel of the Medical Devices Advisory Committee, FDA advisory
committees, for review and recommendation because the information in
the PMA substantially duplicates information previously reviewed by the
panel. On June 23, 1997, CDRH approved the application by a letter to
the applicant from the Director of the Office of Device Evaluation,
CDRH.
A summary of the safety and effectiveness data on which CDRH based
its approval is on file in the Dockets Management Branch (address
above) and is available from that office upon written request. Requests
should be identified with the name of the device and the docket number
found in brackets in the heading of this document.
Opportunity for Administrative Review
Section 515(d)(3) of the act authorizes any interested person to
petition, under section 515(g) of the act, for administrative review of
CDRH's decision to approve this application. A petitioner may request
either a formal hearing under 21 CFR part 12 of FDA's administrative
practices and procedures regulations or a review of the application and
CDRH's action by an independent advisory committee of experts. A
petition is to be in the form of a petition for reconsideration under
21 CFR 10.33(b). A petitioner shall identify the form of review
requested (hearing or independent advisory committee) and shall submit
with the petition supporting data and information showing that there is
a genuine and substantial issue of material fact for resolution through
administrative review. After reviewing the petition, FDA will decide
whether to grant or deny the petition and will publish a notice of its
decision in the Federal Register. If FDA grants the petition, the
notice will state the issue to be reviewed, the form of review to be
used, the persons who may participate in the review, the time and place
where the review will occur, and other details.
Petitioners may, at any time on or before February 26, 1998, file
with the Dockets Management Branch (address above) two copies of each
petition and supporting data and information, identified with the name
of the device and the docket number found in brackets in the heading of
this document. Received petitions may be seen in the office above
between 9 a.m. and 4 p.m., Monday through Friday.
This notice is issued under the Federal Food, Drug, and Cosmetic
Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under
authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10)
and redelegated to the Director, Center for Devices and Radiological
Health (21 CFR 5.53).
Dated: October 31, 1997.
Joseph A. Levitt,
Deputy Director for Regulations Policy, Center for Devices and
Radiological Health.
[FR Doc. 98-1942 Filed 1-26-98; 8:45 am]
BILLING CODE 4160-01-F
